Skip to main content
SpringerLink
Log in

Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin

  • Original Articles
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Bone marrow is the primary site of disease in patients with acute lymphoblastic leukemia (ALL) and is frequently involved in patients with non-Hodgkin's lymphoma (NHL). At the time of autologous bone marrow transplantation, marrow grafts from patients with leukemia and lymphoma are often still contaminated by malignant cells, even when such patients achieve complete clinical remission. In this study, we evaluated the potential of anti-B4-blocked-ricin (anti-B4-bR) immunotoxin to eliminate residual ALL and NHL cells from bone marrow. Anti-B4-bR binds to the CD19 antigen, which is B-lineage specific, and, at concentrations of 5×10−9 M or greater, could eliminate more than 3 logs of CD19+ Nalm-6 or Namalwa cells in a 20-fold excess of normal irradiated bone marrow after only 5 hr of incubation. This activity was abrogated by the addition of anti-B4 but not by the presence of galactose, which is the natural ligand for native ricin. Also, when used at these high concentrations, anti-B4-bR showed little nonspecific toxicity against normal hematopoietic progenitors. In conclusion, a single short exposure to anti-B4-bR is capable of inducing high levels of depletion of CD19+ leukemia and lymphoma cells without significant nonspecific toxicity against normal marrow progenitors. Therefore, anti-B4-bR offers an interesting approach to the elimination of B-lineage malignant cells prior to autologous bone marrow transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kersey JH, Weisdorf D, Nesbit ME, LeBien TW, Woods WG, McGlave PB, Kim T, Vallera DA, Goldman AI, Bostrom B, Hurd D, Ramsey NKC: Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med 317:461–467, 1987

    Google Scholar 

  2. Uckun FM, Kersey JH, Haake R, Weisdorf D, Nesbit ME, Ramsey NKC: Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. N Engl J Med 329:1296–1301, 1993

    Google Scholar 

  3. Estrov Z, Grunberger T, Dube ID, Wang YP, Freedman MH: Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N Engl J Med 315:538–542, 1986

    Google Scholar 

  4. Sharp JG, Joshi SS, Armitage JO, Bierman P, Coccia PF, Harrington DS, Kessinger A, Crouse DA, Mann SL, Weisenburger DD: Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 79:1074–1080, 1992

    Google Scholar 

  5. Uckun FM, Kersey JH, Haake R, Weisdorf D, Ramsay NKC: Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging. Blood 79:1094–1104, 1992

    Google Scholar 

  6. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G: Minimal residual disease in childhood B-lineage lymphoblastic leukemia. N Engl J Med 323:448–455, 1990

    Google Scholar 

  7. Jonsson OG, Kitchens RL, Scott FC, Smith RG: Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes. Blood 76:2072–2079, 1990

    Google Scholar 

  8. Ngan BY, Nourse J, Cleary ML: Detection of chromosomal translocation 5(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 73:1759–1762, 1989

    Google Scholar 

  9. Gribben JG, Freedman AS, Woo SD, Blake K, Shu RS, Freeman G, Longtine JA, Pinkus GS, Nadler LM: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275–3280, 1991

    Google Scholar 

  10. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85–86, 1993

    Google Scholar 

  11. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D, Löwenberg R, Verdonck LF, de Planque M, Hermans J, Helbig W, Porcellini A, Rizzoli V, Alesandrino EP, Franklin IM, Reiffers J, Colleselli P, Goldman JM: Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A european survey of the role of marrow purging. Blood 75:1606–1614, 1990

    Google Scholar 

  12. Rowley SD, Jones RJ, Piantadosi S, Braine HG, Colvin OM, Davis J, Saral R, Sharkis S, Wingard J, Yeager AM, Santos GW: Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 74:501–506, 1989

    Google Scholar 

  13. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525–1533, 1991

    Google Scholar 

  14. Lambert JM, McIntyre G, Gauthier MN, Zullo D, Rao V, Steeves RM, Goldmacher VS, Blättler WA: The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry 30:3234–3247, 1991

    Google Scholar 

  15. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blättler WA: An immunotoxin prepared with blocked ricin: A natural plant toxin adapted for therapeutic use. Cancer Res 51:6236–6242, 1991

    Google Scholar 

  16. Nadler LM: B cell/Leukemia panel workshop: Summary and comments.In Leukocyte Typing II, Vol 2, EL Reinherz, FB Haynes, L Nadler, ID Bernstein (eds). New York, Springer-Verlag, 1986, pp 3–43

    Google Scholar 

  17. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF: A monoclonal antibody reactive with normal and leukemic progenitor cells. Leukemia Res 8:521–534, 1984

    Google Scholar 

  18. Roy DC, Felix M, Cannady WG, Cannistra S, Ritz J: Comparative activities of rabbit complements of different ages using an in vitro marrow purging model. Leukemia Res 14:407–416, 1990

    Google Scholar 

  19. Taswell C: Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 126:1614–1619, 1981

    Google Scholar 

  20. Iscove NN, Sciber F, Winterhalter KH: Erythroid colony formation in cultures of mouse and human bone marrow: Analysis of the requirements for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol 83:309–320, 1974

    Google Scholar 

  21. Messner HA, Fauser AA: Culture studies of human pluripotent hemopoietic progenitors. Blut 41:327–333, 1980

    Google Scholar 

  22. Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blättler WA, Epstein CL, Nadler LM: Anti-B4-blocked-ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11:726–737, 1993

    Google Scholar 

  23. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blättler WA, Epstein CL, Nadler LM: Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 81:2263–2271, 1993

    Google Scholar 

  24. Waldman TA: Monoclonal antibodies in diagnosis and therapy. Science 252:1657–1662, 1991

    Google Scholar 

  25. Roy DC, Griffin JD, Belvin M, Blättler WA, Lambert JM, Ritz J: Anti-MY9-blocked-ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells. Blood 77:2404–2412, 1991

    Google Scholar 

  26. Lynch TJ Jr: Immunotoxin therapy of small cell lung cancer N901-blocked ricin for relapsed small cell lung cancer. Chest 103:436S-439S, 1993

    Google Scholar 

  27. Novak-Hofer I, Amstutz HP, Haldemann A, Blaser K, Morgenthaler JJ, Blauenstein P, Schubiger PA: Radioimmunolocalization of neuroblastoma xenografts with chimeric antibody chCE7. J Nucl Med 33:231–236, 1992

    Google Scholar 

  28. Soiffer RJ, Roy DC, Gonin R, Murray C, Anderson KC, Freedman AS, Rabinowe SN, Robertson MJ, Spector N, Pesek K, Mauch P, Nadler LM, Ritz J: Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant 12:243–251, 1993

    Google Scholar 

  29. Roy DC, Gyger M, Bélanger R, Perreault C, Bonny Y, Soiffer R, Esseltine D, Ritz J: Engraftment following autologous bone marrow transplantation with Anti-B4-bR depleted marrow for patients with B-cell malignancies. Blood 82 (Suppl 1):81a, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Immunology, Maisonneuve-Rosemont Hospital, Department of Medicine, Université de Montréal, Québec, Canada

    Denis C. Roy, Claude Perreault, Robert Bélanger, Martin Gyger & Christiane Le Houillier

  2. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts

    Jerome Ritz

  3. ImmunoGen Inc., Cambridge, Massachusetts

    Walter A. Blättler & John M. Lambert

Authors
  1. Denis C. Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claude Perreault
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Bélanger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Gyger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christiane Le Houillier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Walter A. Blättler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John M. Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jerome Ritz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roy, D.C., Perreault, C., Bélanger, R. et al. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. J Clin Immunol 15, 51–57 (1995). https://doi.org/10.1007/BF01489490

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01489490

Key words

Search

Navigation